Zydus receives final approval from the USFDA for Tadalafil Tablets USP, 20 mg

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Tadalafil Tablets USP, 20 mg (USRLD: Adcirca Tablets, 20 mg).

Tadalafil relaxes muscles of the blood vessels and increases blood flow to particular areas of the body. It is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women. The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).

Tadalafil Tablets USP, 20 mg had annual sales of USD 61 mn in the United States (IQVIA MAT April 2023).

The group now has 369 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 515.00 as compared to the previous close of Rs. 515.50. The total number of shares traded during the day was 28184 in over 1417 trades.

The stock hit an intraday high of Rs. 518.70 and intraday low of 509.05. The net turnover during the day was Rs. 14527785.00.

(*as of 31st March 2023)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 FinalApproval USFDA TadalafilTablets